← back to search

Oğuz Akın

Manhattan Scientifics (United States) · US
Area of research
Pulmonary and Respiratory Medicine · Radiology, Nuclear Medicine and Imaging
Research interest
Research interests include Prostate Cancer Diagnosis and Treatment, Renal cell carcinoma treatment, MRI in cancer diagnosis, and Radiomics and Machine Learning in Medical Imaging.
h-index
56
citations
10,224
works
1,168
NIH funding
primary concept
Medicine
email

Recent publications

SELFIE: Self-Supervised Learning for Fast Dynamic Golden-Angle Radial MRI.
2026cited by 0position: contributordoi
Dual-Stage AI Model for Enhanced CT Imaging: Precision Segmentation of Kidney and Tumors.
2025cited by 4position: contributordoi
Data from Associations between Pretreatment Body Composition Features and Clinical Outcomes among Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Immune Checkpoint Blockade
2025cited by 0position: contributordoi
Supplementary Tables S1-S5 from Associations between Pretreatment Body Composition Features and Clinical Outcomes among Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Immune Checkpoint Blockade
2025cited by 0position: contributordoi
Supplementary Figures S1-S3 from Associations between Pretreatment Body Composition Features and Clinical Outcomes among Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Immune Checkpoint Blockade
2025cited by 0position: contributordoi
Supplementary Tables S6-S8 from Associations between Pretreatment Body Composition Features and Clinical Outcomes among Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Immune Checkpoint Blockade
2025cited by 0position: contributordoi
Radiodensities of Skeletal Muscle and Visceral Adipose Tissues Are Prognostic Factors in Clear-Cell Renal Cell Carcinoma.
2024cited by 8position: contributordoi
Molecular Heterogeneity and Immune Infiltration Drive Clinical Outcomes in Upper Tract Urothelial Carcinoma
European Urology 2024cited by 7position: middledoi
Data from Radiodensities of Skeletal Muscle and Visceral Adipose Tissues Are Prognostic Factors in Clear-Cell Renal Cell Carcinoma
2024cited by 0position: contributordoi
Supplementary Table S1 from Radiodensities of Skeletal Muscle and Visceral Adipose Tissues Are Prognostic Factors in Clear-Cell Renal Cell Carcinoma
2024cited by 0position: contributordoi
Supplementary Table S2 from Radiodensities of Skeletal Muscle and Visceral Adipose Tissues Are Prognostic Factors in Clear-Cell Renal Cell Carcinoma
2024cited by 0position: contributordoi
Supplementary Table S3 from Radiodensities of Skeletal Muscle and Visceral Adipose Tissues Are Prognostic Factors in Clear-Cell Renal Cell Carcinoma
2024cited by 0position: contributordoi
Alliance A021806: A phase III trial evaluating perioperative versus adjuvant therapy for resectable pancreatic cancer.
Journal of Clinical Oncology 2023cited by 29position: middledoi
Supplementary Figures S1-S3 from Associations between Pretreatment Body Composition Features and Clinical Outcomes among Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Immune Checkpoint Blockade
2023cited by 0position: contributordoi
Supplementary Tables S1-S5 from Associations between Pretreatment Body Composition Features and Clinical Outcomes among Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Immune Checkpoint Blockade
2023cited by 0position: contributordoi
Supplementary Tables S1-S5 from Associations between Pretreatment Body Composition Features and Clinical Outcomes among Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Immune Checkpoint Blockade
2023cited by 0position: contributordoi
Data from Associations between Pretreatment Body Composition Features and Clinical Outcomes among Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Immune Checkpoint Blockade
2023cited by 0position: contributordoi
Supplementary Tables S6-S8 from Associations between Pretreatment Body Composition Features and Clinical Outcomes among Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Immune Checkpoint Blockade
2023cited by 0position: contributordoi
Supplementary Figures S1-S3 from Associations between Pretreatment Body Composition Features and Clinical Outcomes among Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Immune Checkpoint Blockade
2023cited by 0position: contributordoi
Supplementary Tables S6-S8 from Associations between Pretreatment Body Composition Features and Clinical Outcomes among Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Immune Checkpoint Blockade
2023cited by 0position: contributordoi
MRI-guided focused ultrasound focal therapy for patients with intermediate-risk prostate cancer: a phase 2b, multicentre study
The Lancet Oncology 2022cited by 80position: middledoi
Associations between Pretreatment Body Composition Features and Clinical Outcomes among Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Immune Checkpoint Blockade.
2022cited by 30position: contributordoi
ACR Appropriateness Criteria® Staging and Surveillance of Testicular Cancer: 2021 Update
Journal of the American College of Radiology 2022cited by 10position: middledoi
Preoperative exercise interventions to optimize continence outcomes following radical prostatectomy
Nature Reviews Urology 2021cited by 90position: middledoi
LGAN: Lung segmentation in CT scans using generative adversarial network
Computerized Medical Imaging and Graphics 2021cited by 73position: contributordoi
Preoperative exercise interventions to optimize continence outcomes following radical prostatectomy.
2021cited by 59position: contributordoi
Small Molecule, Multimodal, [<sup>18</sup>F]-PET and Fluorescence Imaging Agent Targeting Prostate-Specific Membrane Antigen: First-in-Human Study.
2021cited by 20position: contributordoi
Somatic mutations as preoperative predictors of metastases in patients with localized clear cell renal cell carcinoma – An exploratory analysis
Urologic Oncology Seminars and Original Investigations 2021cited by 10position: middledoi
Somatic mutations as preoperative predictors of metastases in patients with localized clear cell renal cell carcinoma - An exploratory analysis.
2021cited by 10position: contributordoi
Effects of fluorodeoxyglucose magnetic nanoparticles on NCI-H727 and SH-SY5Y cancer cells.
2021cited by 2position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

· 24 papers (2020–2026)A. Ari Hakimi · Manhattan Scientifics (United States)21 papers (2014–2025)Marina Mourtzakis · Vance-Granville Community College17 papers (2022–2025)Andrea Knezevic · University of Zagreb17 papers (2022–2025) · 17 papers (2022–2025)Jessica Scott · Weill Cornell Medicine17 papers (2022–2025)Alejandro Sanchez · Hospital Universitario Virgen del Rocío17 papers (2022–2025)Helena Furberg · Cancer Research And Biostatistics17 papers (2022–2025)Cihan Duzgol · Andover Eye Associates14 papers (2020–2025)Robert J. Motzer · Texas Oncology13 papers (2014–2025)Chung-Han Lee · Exelixis (United States)12 papers (2022–2025) · 12 papers (2022–2025) · 12 papers (2022–2025)Joshua Chaim · Manhattan Scientifics (United States)12 papers (2022–2025)Ritesh R. Kotecha · Spanish Oncology Genitourinary Group12 papers (2022–2025)Emily Stein · Medidata (United States)12 papers (2022–2025)Michael T. Paris · University of Waterloo12 papers (2022–2025)Stacey Petruzella · Memorial Sloan Kettering Cancer Center12 papers (2022–2025)Martin H. Voss · Spanish Oncology Genitourinary Group12 papers (2022–2025)Sujata Patil · Government Ayurvedic College and Hospital12 papers (2022–2025)